Eutilex - Model EU301(MVR CAR-T) -Relapsed and Refractory B Cell Leukemia and B Cell Lymphoma

MVR CAR-T can be used against HLA-DR positive cancer, as well as B cell malignancy. The epitopes recognized by HLA-DR are not shed or internalized, enabling stable binding to human lymphoma cells. MVR CAR-T can also be used in patients who relapse after CD19 CAR-T treatment. Reduction of cytokine secretion due to selective killing of tumor cells.